Naltrexone is an opioid antagonist that, according to the FDA labeling, can reduce or virtually eliminate cravings. Medical practitioners that have used the implantable pellets have informed us that they last multiple months; however, we cannot recommend or promote such use. Naltrexone, while it has been FDA approved in pill form since 1984 for OUD and 1995 for AUD, subcutaneous placed pellets have not. Naltrexone is also FDA approved in an injectable form for the same disorders.
MAT programs may utilize naltrexone, sometimes in the form of a naltrexone implant, or other medications such as buprenorphine and methadone. Below is a comparison of the three commonly used MAT medications and is provided for informational purposes only and should not be construed as a recommendation or promotion of any drug for any purpose. The basis of a physician’s decision to use a medication, which medication to use, or in which form it should be delivered is solely within the physician’s medical judgement.